Program
BGM0504
Also written as “BGM0504 tablets”, “BGM0504 Administered SC” and “BGM0504 Injection single-dose pen”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight, led by BrightGene Bio-Medical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BrightGene Bio-Medical Technology | 163 open or running | phase 3since Nov 7, 2024 | Nov 7, 2024 | Feb 28, 2027phase 2 · NCT07658560 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 7, 2024.
- Mar 27, 2025Phase 1 study in OverweightNCT06920056 · 28 enrolled · China
- Apr 3, 2025Phase 2 study in ObesityNCT06911203 · 96 enrolled · China
- Apr 8, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06929156 · 34 enrolled · China
- May 14, 20252 phase 2 studiesNCT06974825, NCT06973681
- Jul 11, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07064486 · 152 enrolled · Indonesia
- Sep 3, 2025Phase 1 study in ObesityNCT07166081 · 80 enrolled · United States
- Nov 13, 2025Phase 1 study in ObesityNCT07239973 · 75 enrolled · China
- Jan 26, 2026Phase 1 study in OverweightNCT07382908 · 144 enrolled · China
- Apr 22, 2026Phase 1 study in Chinese Healthy VolunteersNCT07566572 · 144 enrolled · China
- Jun 11, 2026Phase 2 study in OverweightNCT07658560 · 200 planned · China
- Jul 24, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07743983 · 372 planned · China
- Oct 13, 2026Primary completion moved from 2026-07-31 to 2027-04-30Date moved laterphase 3 · +9 months · NCT07064486
- Oct 15, 2026Primary completion moved from 2025-12-29 to 2026-11-14Date moved laterphase 3 · +11 months · NCT06716203
- Oct 15, 2026Primary completion moved from 2026-03-20 to 2026-11-14Date moved laterphase 3 · +8 months · NCT06716216
Ahead
- Feb 28, 2027Primary completion: phase 2 study in OverweightNCT07658560
- Apr 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07064486
- Sep 30, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07743983
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07743983Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Sep 30, 2028 | 372 |
| NCT07658560Overweight · China | 2 | Recruiting | Feb 28, 2027 | 200 |
| NCT07566572Chinese Healthy Volunteers · China | 1 | Completed | Aug 31, 2026 | 144 |
| NCT07382908Overweight · China | 1 | Completed | Apr 9, 2026 | 144 |
| NCT07239973Obesity · China | 1 | Completed | Mar 5, 2026 | 75 |
| NCT07166081Obesity · United States | 1 | Completed | Mar 16, 2026 | 80 |
| NCT07064486Diabetes Mellitus, Type 2 · Indonesia | 3 | Active, not recruiting | Apr 30, 2027 | 152 |
| NCT06974825Diabetes Mellitus, Type 2 · China | 2 | Completed | Aug 13, 2024 | 67 |
| NCT06973681Overweight · China | 2 | Completed | Sep 13, 2024 | 120 |
| NCT06929156Diabetes Mellitus, Type 2 · China | 1 | Completed | Dec 25, 2025 | 34 |
| NCT06911203Obesity · China | 2 | Completed | Jan 14, 2026 | 96 |
| NCT06920056Overweight · China | 1 | Completed | Jul 25, 2025 | 28 |
| NCT06716216Diabetes Mellitus, Type 2 · China | 3 | Completed | Aug 25, 2026 | 553 |
| NCT06716203Diabetes Mellitus, Type 2 · China | 3 | Completed | Aug 13, 2026 | 227 |
| NCT06714955Obesity · United States | 1 | Completed | Jan 21, 2025 | 30 |
| NCT06704581Overweight · China | 3 | Completed | Mar 17, 2026 | 652 |
How it is read
Names in the registry
- “BGM0504”, 16 entries
- “BGM0504 tablets”, 6 entries
- “BGM0504 Administered SC”, 3 entries
- “BGM0504 Injection single-dose pen”, 2 entries
- “Drug: 5 mg BGM0504 Administered SC”, 1 entry
Codes read as this program: BGM0504.
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Diabetes Mellitus, Type 2, 6 studies
- Overweight, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.